Abstract:Purpose: We determined the differential cyclic guanyl monophosphate catalytic and cyclic guanyl monophosphate binding activity of phosphodiesterase-5 isoforms and the inhibitory effects of sildenafil (Pfizer, New York, New York) and vardenafil (Bayer Pharmaceutical Research, Wuppertal, Germany). Materials and Methods: Coding sequences of the human phosphodiesterase-5 isoforms A1, A2 and A3 were cloned into pBlueBac4.5N5-His (Invitrogen, Carlsbad, California), which allows the tagging of histidines at the carboxyl terminal of the expressed protein. Isoforms were expressed with the Bac-N-Blue (TM) baculoviral system and purified with the ProBond (TM) system. Expression clones were identified by polymerase chain reaction using vector and phosphodiesterase-5 specific primers. Purified proteins were verified by Western blotting. Purified proteins were analyzed for cyclic guanyl monophosphate catalytic and cyclic guanyl monophosphate binding activity, and used to determine the differential potencies of the phosphodiesterase-5 selective inhibitors sildenafil and vardenafil. Results: Cloning and expression of phosphodiesterase-5A1 to A3 isoforms in the baculoviral system resulted in the isolation of purified isoform proteins. Mean cyclic guanyl monophosphate catalytic activity (M-m) SD was 4.76 +/- 0.37, 4.52 +/- 0.09 and 11.39 +/- 0.22 mu M for A1 to A3, respectively. Mean cyclic guanyl monophosphate binding activity (K-d) was 3.24 +/- 0.47, 1.95 +/- 0.60 and 1.70 +/- 0.47 mu M for A1 to A3, respectively. Mean IC50 of sildenafil against phosphodiesterase-5A1 to A3 was 1.20 +/- 0.34, 2.83 +/- 0.56 and 2.28 +/- 0.38 nM, respectively. Mean lC(50) of vardenafil against phosphodiesterase-5A1 to A3 was 0.41 +/- 0.15, 0.23 +/- 0.08 and 0.45 +/- 0.06 nM, respectively. Conclusions: Phosphodiesterase-5A1 and A2 had similar K. values, while phosphodiesterase-5A3 had a much higher K-m and, thus, lower cyclic guanyl monophosphate catalytic activity. Phosphodiesterase-5A2 and A3 had similar K, values, while phosphodiesterase-5A1 had higher Kd and, thus, lower cyclic guanyl monophosphate binding activity. Vardenafil was more potent (3 to 12-fold) than sildenafil for inhibiting the catalytic activity of all 3 human phosphodiesterase-5 isoforms with phosphodiesterase-5A2 showing the highest differentiation (12-fold).

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

Expression, Distribution And Regulation Of Phosphodiesterase 5

The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding

Multiple Conformations of Phosphodiesterase-5: Implications for Enzyme Function and Drug Development.

Phosphodiesterase-5 Isoforms: Differential Cyclic Guanyl Monophosphate Binding and Cyclic Guanyl Monophosphate Catalytic Activities, and Inhibitory Effects of Sildenafil and Vardenafil

Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes

Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta

[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]

Abstract Mo139: PDE1, 3 and 4 Inhibition and GPCR Agonism in the Regulation of cAMP Signaling

Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism.

Overview of PDEs and Their Regulation

Phosphodiesterases coordinate cAMP propagation induced by two stimulatory G protein-coupled receptors in hearts

Specific phosphorylation sites underlie the stimulation of a large conductance, Ca2+-activated K+ channel by cGMP-dependent protein kinase

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

Immunolocalization of multidrug resistance protein 5 in the human genitourinary system

Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action

Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation

PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes

In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum of freely moving rats

Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health

In vivo experiments using soluble guanylyl cyclase Beta1 his 105 Phe mutant mice: no-vasodilatation and penile erection fully dependent on activation of SGC